Company
Valora Therapeutics, Inc.
Target. Decoy. Engage Immunity.
- Business model
- B2B
- Legal name
- Valora Therapeutics Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Valora Therapeutics is developing AbLec™ multispecific antibodies and T-Lec™ T cell engagers — antibody-engineering platforms that decoy the glyco-immune checkpoint to create best-in-class therapeutics for cancer and autoimmune disease.
Funding snapshot
- Total raised
- $13MSEC form D sum, as of 2026-09-29Source (opens in a new tab)
- Latest round
- Round, $13M2024-07-09
Funding rounds
- Round, 2024
- $13M2024-07-09, SEC form D sold, 12 investors
Loading relationship preview